A Nice Problem to Have?

After scientists raced to develop a Zika vaccine following the 2015 outbreak, a $110 million trial is underway. But here’s the irony: Infection rates are so low that it’s impossible to test whether the vaccine works.
It’s “a good dilemma because we don't have Zika anymore,” says the University of São Paulo’s Esper Kallás. But the vaccine might be needed someday. So, investigators are reconsidering the option of infecting people deliberately to test the vaccine—an ethically fraught, but not uncommon method for diseases like Zika.
“There's a compelling reason to conduct a human challenge trial now,” but the decision requires careful review, said bioethicist Seema Shah of Northwestern University.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top